Mesenchymal stem cell therapy induces FLT3L and CD1c+ dendritic cells in systemic lupus erythematosus patients

Xinran Yuan1,2,5, Xiaodong Qin3,5, Dandan Wang1,5, Zhuoya Zhang1, Xiaojun Tang1, Xiang Gao2, Wanjun Chen4 & Lingyun Sun1,2

Allogeneic mesenchymal stem cells (MSCs) exhibit immunoregulatory function in human autoimmune diseases such as systemic lupus erythematosus (SLE), but the underlying mechanisms remain incompletely understood. Here we show that the number of peripheral tolerogenic CD1c+ dendritic cells (DCs) and the levels of serum FLT3L are significantly decreased in SLE patients especially with lupus nephritis, compared to healthy controls. Transplantation of allogeneic umbilical cord-derived MSCs (UC-MSCs) significantly up-regulates peripheral blood CD1c+DCs and serum FLT3L. Mechanistically, UC-MSCs express FLT3L that binds to FLT3 on CD1c+DCs to promote the proliferation and inhibit the apoptosis of tolerogenic CD1c+DCs. Conversely, reduction of FLT3L with small interfering RNA in MSCs abolishes the up-regulation of tolerogenic CD1c+DCs in lupus patients treated with MSCs. Interferon-γ induces FLT3L expression in UC-MSCs through JAK/STAT signaling pathway. Thus, allogeneic MSCs might suppress inflammation in lupus through up-regulating tolerogenic DCs.
Syste
mic lupus erythematosus (SLE) is a systemic auto-
immune disease that is characterized by autoantibodies with
immune complexes deposition leading to multi-organ
injury. In spite of the significant variation of disease severity
among SLE patients, the dysregulation of innate and adaptive
immune responses are universal. An insight into the underlying
pathology is important to develop optimal therapies.

Dendritic cells (DCs) are innate immune cells that play key
roles in initiating and regulating immunity by sensing and inte-
grating signals from a wide range of pathogens and tissue
damage. Previous studies about DCs in SLE mainly focused on
the plasmacytoid DCs (pDCs), but the contribution of conven-
tional DCs (cDCs) to SLE pathogenesis remains largely unknown.
Plasticity of DCs with different maturity status and function
allows them to be exploited as tolerogenic DCs for their clinical
application in autoimmune disease. Previous studies have sug-
gested tolerogenic DC subsets in human displaying immunoreg-
ulatory functions, such as CD1c+ DCs in human peripheral
blood and in lymphoid and non-lymphoid tissues. Compared
with other conventional DC subsets, poly I:C-activated
CD1c+ DCs express low levels of co-stimulatory molecules CD40,
CD80, CD83, CD86, as well as stimulatory cytokines such as
interleukin (IL)-12, to induce IFN-γ-secreting T cells. In
response to Escherichia coli (E.coli) stimulation, human periph-
eral CD1c+ DCs produced only low levels of tumor necrosis factor
(TNF), IL-6, IL-12. Instead, they produced high levels of the anti-
inflammatory cytokine IL-10 and regulatory molecules indolea-
mine 2,3-dioxynoxygenase (IDO). These CD1c+ DCs suppressed
T-cell proliferation in an IL-10-dependent manner. Similarly, human
liver resident CD1c+ DCs produced large amounts of IL-10 upon
LPS stimulation and induced immunoregulatory T regulatory
cells and IL-4-producing Th2 cells via an IL-10-dependent
mechanism. Moreover, human pulmonary CD1c+ DCs also
exert tolerogenic properties in inducing Treg by IL-27/IL-10/
inducible costimulator ligand. Thus, certain CD1c+ DCs might
be a crucial DC subtype for ameliorating immune dysfunction
and maintaining immune homeostasis. Although previous studies
have reported the abnormalities of DCs in SLE, the number and
function of tolerogenic CD1c+DC subset in lupus patients remain
largely unknown.

The cytokine Fms-related tyrosine kinase 3-ligand (FLT3L) is a
key regulator of DC commitment in hematopoiesis, which reg-
ulates the proliferation, differentiation and apoptosis of haema-
topoietic cells through the binding to FLT3. Not only do
cDCs proliferation depend on FLT3L, but also CD1c+ DCs, as
well as their precursors could be specifically elevated by injection
of FLT3L in humans and mice. However, researches regarding
FLT3L focused mainly on hematopoietic cells and hematological
diseases, but few in autoimmune diseases.

Mesenchymal stem cells (MSCs) are non-hematopoietic stem
cells that can support the function of hematopoietic stem cells
(HSCs) in bone marrow. MSCs possess immunomodulatory
properties and functions to immune cells, including T, B, NK
cells and macrophages. MSCs also regulate DC function by
inhibiting their co-stimulatory molecule expression and pro-
inflammatory cytokine production, leading to the suppression
of their capacity to initiate naive T cells and immune responses.
Moreover, it is reported that the immunosuppressive function
of MSCs is enhanced by pro-inflammatory cytokines such as
interferon-γ (IFN-γ). We have previously shown that
CD8+ T cells derived IFN-γ in SLE patients induced MSCs to
secrete large amount of IDO that suppressed T cell proliferation.
Meanwhile, the serum levels of IFN-γ in SLE patients could
predict MSCs therapeutic effect. However, whether MSCs regu-
late tolerogenic DCs in lupus proinflammatory environment
remains unknown.

Here, we determine that the decreased number of tolerogenic
CD1c+ DCs due to the deficiency of FLT3L contributes to the
pathogenesis of SLE. Allogeneic UC-MSCs promote the pro-
liferation and inhibit the apoptosis of tolerogenic CD1c+ DCs by
up-regulating FLT3L in SLE patients, which could be enhanced
by the high level of IFN-γ in lupus environment. Thus, we uncover a previous unrecognized IFN-γ/FLT3L-FLT3/
CD1c+ DCs axis that mediates the therapeutic benefit of allo-
gegenic UC-MSCs in lupus.

Results

CD1c+DCs decrease in SLE patients. We first investigated
the numbers of peripheral blood CD1c+ DCs in patients with
SLE by flow cytometry. CD1c+ DCs were defined as Lin (CD3/19/
56/14)+HLA-DR+CD11c+CD1c+ (Fig. 1a). The number of
CD1c+ DCs in SLE patients was markedly decreased compared to
healthy controls (HC) (Fig. 1b, c, d) and patients with rheumatoid
arthritis (RA) (Supplementary Fig. 1). The number of CD1c+ DCs
was negatively correlated with systemic lupus erythematosus
disease activity index (SLEDAI) score (Fig. 1e). Additionally, SLE
patients with lupus nephritis (LN) showed a further reduced
percentage of CD1c+ DCs than those without nephritis (Fig. 1f).
In addition, the number of CD1c+ DCs was negatively correlated
to renal indexes namely 24 h proteinuria (Fig. 1g), blood urea
nitrogen (BUN) (Fig. 1h) and serum creatinine (Scr) (Fig. 1i).
These results all together indicated that CD1c+ DCs might par-
ticipate in the regulation of SLE pathogenesis.

Decreased FLT3L results in CD1c+DCs deficiency. Next, we
studied the underlying mechanisms for the deficiency of CD1c+
DCs in SLE patients. Previous studies have found that FLT3L
injection induced expansion of CD1c+ DCs in human blood, so
we determined FLT3L levels in SLE and HC by real-time PCR
and ELISA. The mRNA level of FLT3L was significantly
decreased in SLE peripheral blood mononuclear cells (PBMCs)
(Fig. 2a), and the protein level in SLE serum was also decreased
(Fig. 2b). In contrast, the mRNA level of FLT3 (CD135) in
PBMCs was significantly increased in SLE patients compared
with healthy controls (Fig. 2c). There was a trend towards that
FLT3L was negatively correlated with FLT3 (Fig. 2d). Although
both FLT3L and CD1c+ DCs were significantly decreased, and
FLT3 was significantly increased in SLE patients, the changes
of FLT3 and its ligand were smaller than that of CD1c+ DCs in
SLE patients. To determine whether FLT3L could up-regulate
CD1c+ DCs in vitro, SLE PBMCs were stimulated with different
concentrations of recombinant human FLT3L (1, 10, 100 and
500 ng/ml). After stimulation for 48 h, we found that FLT3L up-
regulated the number of CD1c+ DCs in SLE PBMCs, with statistical
difference at a concentration of 10 ng/ml (Fig. 2e, Supplementary Fig. 2). FLT3L could also up-regulate the num-
er of CD1c+ DCs in PBMCs obtained from healthy subjects
(Supplementary Fig. 3). These data suggested that decreased
level of FLT3L in SLE patients might result in the deficiency of
CD1c+ DCs.

UC-MSCs ameliorate CD1c+DCs deficiency in SLE patients.
Twenty-one SLE patients, who were refractory to conventional
therapies, underwent UC-MSCs transplantation (U-MSCT). The
clinical features and medication history of the SLE patients
underwent U-MSCT are listed in Tables 1, and 2 and Supple-
mentary Table 1. No serious adverse events were found during
24 h and/or 72 h after infusions of UC-MSCs in any of the 21 SLE
patients. No treatment-related mortality or other adverse
events occurred during or after U-MSCT, and U-MSCT was well
tolerated by all patients.
The peripheral blood Lin−HLA-DR−CD11c+CD1c+DCs were analyzed before and after U-MSCT. The frequency and absolute number of CD1c+DCs were significantly increased 24 h and 72 h after U-MSCT (Fig. 3a, c, e–g). In addition, serum FLT3L levels also increased after U-MSCT (Fig. 3d, h). The first 11 patients had completed 6-month follow-up. The SLEDAI score remarkably declined after U-MSCT at 6-month follow-up (Fig. 3i). Two patients (patient 2 and 11) showed complete remission with SLEDAI scores <3 at 6-month follow-up. Seven patients showed partial remission with SLEDAI scores <8 at 6-month follow-up. Two patients (patient 7 and 8) had a flare of disease with SLEDAI scores ≥8 at their 6-month follow-up, respectively, among which, one patient had renal transplantation 15 months after MSCs transplantation (patient 7), the other had renal dialysis 12 months after MSCs transplantation (patient 8). The last 10 patients have completed 1-month follow-up. The SLEDAI score remarkably declined after U-MSCT at 1-month follow-up (Supplementary Fig. 5). Six patients showed partial remission with SLEDAI scores <8 at 1-month follow-up (remission group), and the other four patients showed no remission with SLEDAI scores ≥8 at their 1-month follow-up (no remission group). The increase of CD1c+DCs was significantly larger in remission group compared with no remission group (Supplementary Fig. 6). In addition, there were no significant changes of pDCs (Lin−HLA-DR−CD11c−CD123+ or CD141+DCs (Lin−HLA-DR−CD11c−CD141+) after U-MSCT (Supplementary Fig. 7, 8). Furthermore, rather than U-MSCT, the lupus nephritis patients who achieved partial remission after regular medication therapy showed no significant change of CD1c+DCs number (Supplementary Fig. 9).

Since LN patients showed a much lower number of CD1c+DCs, and the frequency of CD1c+DCs was correlated to renal indexes, we followed-up the renal involvement 6 months after U-MSCT. The level of 24 h proteinuria significantly decreased (Fig. 3j), but the levels of BUN (Fig. 3k) and Scr (Fig. 3l) had no significant change.

Next, PBMCs from patients with SLE were co-cultured with UC-MSCs at ratios of 1:1 and 10:1 in vitro, and we found UC-MSCs significantly up-regulated the frequency of CD1c+DCs in indirect transwell culture group (Fig. 3p). In addition, there were no significant changes of pDCs.
were no significant changes of pDCs or CD141+DCs in PBMCs when co-cultured with UC-MSCs (Supplementary Figs 12, 13).

In addition, since in vivo the function of CD1c+DCs is influenced by their environment and they can be matured into immunogenic cells by other stimuli such as CD40 ligand (CD40L) and toll-like receptor (TLR) activation, both of which are likely to occur in lupus patients, we next investigated the function of the UC-MSCs induced CD1c+DCs in the lupus patients, by their functional markers (CD40/CD80/CD83/CD86 expression), ability to present antigen (HLA-DR expression) and cytokines production including IL-10 and TNFα. The peripheral blood CD1c+DCs were analyzed before and after U-MSCT in the last 10 patients (Supplementary Table 1, patient 12–21). We found that after U-MSCT, the expression of the co-stimulatory molecules and HLA-DR of CD1c+DCs in freshly isolated peripheral blood of treated SLE did not change significantly. However, LPS-mediated upregulation of CD80, CD86 and HLA-DR expressions of CD1c+DCs were significantly decreased in SLE patients after MSCs transplantation compared to before treatment (Fig. 3q, r); similarly, LPS-induced TNFα produced by CD1c+DCs in SLE PBMCs were also significantly decreased after MSCs transplantation (Fig. 3s), whereas the level of IL-10 showed

**Table 1 Patients’ baseline clinical characteristics**

| Patient | Age/sex | Disease duration (months) | Baseline SLEDAI | Clinical manifestation |
|---------|---------|---------------------------|-----------------|-----------------------|
| 1       | 41/F    | 120                       | 15              | LN, A, C, F, ANA+, anti-dsDNA+, anti-SM+, |
| 2       | 37/F    | 36                        | 13              | LN, A, C, H, ANA+, anti-dsDNA+ |
| 3       | 26/F    | 84                        | 14              | LN, A, C, F, H, P, ANA+, anti-SM+ |
| 4       | 51/F    | 192                       | 15              | LN, C, H, ANA+, anti-dsDNA+, anti-SM+ |
| 5       | 31/M    | 48                        | 21              | LN, C, H, P, ANA+, anti-dsDNA+, anti-SM+ |
| 6       | 55/F    | 180                       | 11              | LN, A, C, H, ANA+ |
| 7       | 21/M    | 96                        | 14              | LN, A, C, F, ANA+, anti-SM+ |
| 8       | 38/F    | 84                        | 28              | LN, A, C, H, P, V, ANA+, anti-dsDNA+, anti-SM+ |
| 9       | 44/F    | 96                        | 13              | LN, A, F, H, ANA+, anti-dsDNA+, anti-SM+ |
| 10      | 29/M    | 102                       | 11              | LN, C, F, ANA+, anti-dsDNA+, anti-SM+ |
| 11      | 26/F    | 120                       | 13              | LN, C, F, H, P, ANA+, anti-dsDNA+, anti-SM+ |

A, arthralgia; ANA, antinuclear antibody; anti-dsDNA, anti double strand DNA antibody; C, cytopenia; F, febrile; H, hypocomplementemia; LN, lupus nephritis; P, polyserositis; V, vasculitis
no significant change after U-MSCT (Fig. 3i). Upon CD40L stimulation, the level of TNFa of CD1c+DCs significantly decreased after U-MSCT (Supplementary Fig. 14), while the level of IL-10 showed no significant change after U-MSCT (Supplementary Fig. 15). In addition, we studied the functional change of CD1c+DCs in SLE PBMCs after co-cultured with MSCs. Consistent to the above in vivo data, upon LPS stimulation, the expression of FLT3L on PBMCs was significantly increased when co-cultured with UC-MSCs than without UC-MSCs (Fig. 3u, v, w). Whereas there was no significant difference of IL-10 production between the two groups (Fig. 3x).

Collectively, our data demonstrated that in lupus microenvironment, UC-MSCs not only increased the number of CD1c+DCs, but also drove CD1c+DCs towards a more tolerogenic phenotype.

UC-MSCs up-regulate CD1c+DCs via FLT3L. Next, we wanted to verify whether FLT3L played a role in the up-regulation of CD1c+DCs by MSCs. First, we demonstrated UC-MSCs expressed FLT3L by immunofluorescence and flow cytometry (Fig. 4a, b). As expected, by flow cytometry we demonstrated CD1c+DCs expressed FLT3 (Fig. 4c). Moreover, by real-time PCR, compared with CD4+T cells and CD19+B cells, CD1c+DCs expressed much higher level of FLT3 (Fig. 4d). To confirm the role of FLT3L on UC-MSCs in the up-regulation of CD1c+DCs, we inhibited FLT3L expression on UC-MSCs with FLT3L siRNA (Fig. 4e, Supplementary Fig. 16) and found that the reduction of FLT3L abrogated the up-regulation of CD1c+DCs by UC-MSCs (Fig. 4f). Although the expression levels of IL-6 and HGF on UC-MSCs were significantly higher than FLT3L (Supplementary Fig. 17), inhibiting IL-6 or HGF on UC-MSCs with siRNA had no effect on the ability of UC-MSCs to up-regulate CD1c+DCs (Supplementary Figs. 18, 19, 20). These data suggested that FLT3L produced by UC-MSCs predominantly mediated the up-regulation of CD1c+DCs in lupus patients.

To understand the mechanisms by which allogeneic UC-MSCs increase CD1c+DCs, we first exclude the possibility that UC-MSCs indirectly regulate CD1c+DCs via other cells in PBMCs. The UC-MSCs could significantly up-regulate CD1c+DCs in CD4+CD8−PBMCs (T cell-depleted PBMCs), which basically concluded that UC-MSCs up-regulating CD1c+DCs was T cells-independent (Supplementary Fig. 21). Although the expression of FLT3L on PBMCs was significantly higher than that on UC-MSCs (Fig. 4g), the autologous PBMCs (CD1c+DCs depleted) could not up-regulate CD1c+DCs in PBMCs like UC-MSCs did (Fig. 4h). Hence, we could basically exclude the possibility that UC-MSCs indirectly regulate CD1c+DCs via PBMCs. Then in order to detect whether UC-MSCs directly act on CD1c+DCs, we isolated CD1c+DCs from healthy subjects and cultured with UC-MSCs. We found that UC-MSCs significantly increased the proliferation (Fig. 4i) and decreased the apoptosis of CD1c+DCs (Fig. 4j). Importantly, knockdown of FLT3L with specific siRNA significantly reduced the effects of UC-MSCs on the proliferation and apoptosis of CD1c+DCs (Supplementary Fig. 22). Moreover, we co-cultured UC-MSCs with the PBMCs in which the CD1c+DCs were depleted, and found UC-MSCs could not drive CD1c−PBMCs to differentiate into CD1c+DCs (Supplementary Fig. 22).

Our findings suggested a key role of FLT3L in MSCs-mediated increase in tolerogenic CD1c+DCs.

IFN-γ increases FLT3L in UC-MSCs. To investigate whether inflammatory microenvironment in lupus patients influence FLT3L expression of UC-MSCs, we stimulated UC-MSCs with IFN-γ (20 ng/ml), as SLE patients show increased IFN-γ. Indeed, IFN-γ enhanced FLT3L expression on UC-MSCs (Fig. 5a). Interestingly, SLE PBMCs and serum also increased the expression of FLT3L on UC-MSCs, while HGF PBMCs and serum did not (Fig. 5b, c). The addition of anti-IFN-γ antibody inhibited FLT3L expression on UC-MSCs and consequently abolished the increase of CD1c+DCs when co-cultured with SLE PBMCs (Fig. 5d, e). Furthermore, stimulation of UC-MSCs with SLE PBMCs activated JAK/STAT signaling pathways and up-regulated FLT3L protein, which was abrogated by anti-IFN-γ antibody (Fig. 5f, g, Supplementary Fig. 23, 24). In addition, AG490, a specific inhibitor of JAK/STAT, decreased the expression of FLT3L in UC-MSCs stimulated with IFN-γ or SLE PBMCs (Fig. 5h). The data altogether indicate that JAK/STAT pathway is involved in the up-regulation of FLT3L on UC-MSCs induced by IFN-γ or SLE PBMCs.

Discussion
The mechanisms that account for UC-MSCs-mediated immunoregulation in lupus patients remain incompletely understood. Herein we have uncovered that UC-MSCs increased tolerogenic CD1c+ DCs through FLT3L–FLT3 interaction, which could be enhanced by IFN-γ.

In SLE, the breakdown of immune tolerance is widespread and involves autoantigens present in several cell types, making the design of antigen-specific therapy difficult. Current lupus therapies inhibiting both T and B lymphocytes, carry risk of adverse events such as infection. B cell-selective monoclonal antibodies targeting CD20

| Patient | Treatment before U-MSCT | Treatment 6-mo after U-MSCT |
|---------|-------------------------|-----------------------------|
| 1       | Pred 15 mg/d, CYC 0.8 gm/mo, LEF 20 mg/d, HCQ 0.4 gm/d (<26 mo) | Pred 5 mg/d, HCQ 0.4 gm/d |
| 2       | Pred 30 mg/d, CYC 0.8 gm/mo (<16 mo), MMF 1 gm/d (<14 mo) | Pred 5 mg/d, MMF 1 gm/d, HCQ 0.2 gm/d |
| 3       | Pred 20 mg/d, LEF 20 mg/d, Tacrolimus 3 mg/d, HCQ 0.2 gm/d (<34 mo) | Pred 5 mg/d, Tacrolimus 15 mg/d, HCQ 0.2 gm/d |
| 4       | Pred 20 mg/d, CYC 0.8 gm/mo, HCQ 0.2 gm/d (<8 mo) | Pred 5 mg/d, HCQ 0.2 gm/d |
| 5       | Pred 35 mg/d, MMF 1.5 gm/d, HCQ 0.4 gm/d (<16 mo) | Pred 5 mg/d |
| 6       | Pred 10 mg/d, CYC 0.8 gm/mo, HCQ 0.2 gm/d (<12 mo) | Pred 5 mg/d, Cyclosporine 150 mg/d, HCQ 0.2 gm/d |
| 7       | Pred 15 mg/d, CYC 0.8 gm/mo, MMF 1 gm/d (<8 mo) | Pred 10 mg/d, Tacrolimus 2 mg/d, HCQ 0.2 gm/d |
| 8       | Pred 40 mg/d (<1 mo), then tapered to Pred 30 mg/d, CYC 0.8 gm/mo, LEF 20 mg/d, HCQ 0.2 gm/d (<6 mo) | Pred 5 mg/d, HCQ 0.2 gm/d |
| 9       | Pred 20 mg/d, MMF 1.5 gm/d, HCQ 0.4 gm/d (<17 mo) | Pred 10 mg/d, HCQ 0.2 gm/d |
| 10      | Pred 30 mg/d, CYC 1 gm/mo (<12mo), LEF 20 mg/d (<6 mo) | Pred 5 mg/d |
| 11      | Pred 30 mg/d, Tacrolimus 3 mg/d, HCQ 0.2 gm/d (<12 mo) | Pred 5 mg/d, HCQ 0.4 gm/d |

CYC cyclophosphamide, d day, HCQ hydroxychloroquine, LEF leflunomide, MMF mycophenolate mofetil, mo month, Pred prednisone, U-MSCT UC-MSCs transplantation
Our findings revealed that the number of CD1c+DCs in PBMCs in SLE patients decreased compared with healthy controls and RA patients (Supplementary Fig. 1), and the number of CD1c+DCs was negatively correlated with the SLEDAI score and LN-related indexes (Fig. 1e, f, g, h, i), indicating the crucial role of this tolerogenic DC subset in the pathogenesis of SLE, especially in patients with renal abnormalities.

(rituximab) and BAFF (belimumab), despite clinical efficacy in patients with refractory disease, are also associated with long-term treatment-related adverse events. All available medications for managing lupus, including belimumab, work through the same mode of action, namely nonspecific suppression of the immune system.
As a key regulator of DCs hematopoiesis, FLT3L regulates the differentiation, proliferation and apoptosis of peripheral DCs in human and mouse. In this study, we found that the level of FLT3L significantly decreased in peripheral blood in patients with SLE, and human recombinant FLT3L stimulation significantly increased the proportion of CD1c+DCs in lupus PBMCs in vitro. Thus we considered that the defect of FLT3L was at least partly contributed to the deficiency of CD1c+DCs in lupus patients. At odds with our findings, Nakamura and his colleagues reported the serum FLT3L level was slightly higher in patients with SLE compared with normal subjects, but the difference was not statistically significant. This discrepancy could be due to differences in cohort characteristics, the experimental protocols used, or both.

Allogeneic UC-MSCs show unique immunoregulatory functions by suppressing T cell proliferation and inducing the generation of Treg, inhibiting B cell function and IgG production, or promoting the phagocytic activity of macrophage. Whether DCs could be regulated by UC-MSCs in lupus microenvironment is rarely known. Our findings revealed that UC-MSCs significantly up-regulated the number of CD1c+DCs via FLT3L in a time-dependent manner (Fig. 3f, g, m). In support of this conclusion, we demonstrated that UC-MSCs transplantation remarkably up-regulated the level of serum FLT3L along with an increase of CD1c+DCs in lupus patients. Meanwhile, siRNA against FLT3L could abrogate the up-regulation of CD1c+DCs by UC-MSCs.

We further explored the mechanism by which UC-MSCs increased CD1c+DCs via FLT3L. We reviewed the database of the gene-annotation portal BioGPS (http://biogps.org/gotools#&goto=genepert&id=2323), and found among mononuclear cells, T cells had the highest expression of FLT3L. Moreover, the expression of FLT3L on PBMCs was significantly higher than that on UC-MSCs (Fig. 4g). Therefore, there was a possibility that UC-MSCs indirectly regulate CD1c+DCs via FLT3L in other cells of PBMCs. In order to investigate the contribution of FLT3L on T cells in PBMCs to the increase of CD1c+DCs, the CD4+ and CD8+ T cells were extracted from PBMCs. After co-cultured with UC-MSCs, the frequency of CD1c+DCs in CD4-CD8- PBMCs (T cell-depleted PBMCs) was significantly increased as well (Supplementary Fig. 2f), which could basically exclude the possibility that UC-MSCs indirectly regulate CD1c+DCs via T cells. Furthermore, in order to study the contribution of FLT3L on PBMCs to the increase in CD1c+DCs, we co-cultured PBMCs with UC-MSCs (PM group) or autologous PBMCs in which the CD1c+DCs were depleted (PP group). After co-culture for 72 h, the frequency of CD1c+DCs was significantly higher in PM group than that in PP group. Moreover, the neutralizing antibody against FLT3L was added to both PM and PP groups, the up-regulation of CD1c+DCs was abolished in PM group, while there was no significant change of CD1c+DCs in PP group (Fig. 4h). Hence, we could basically exclude the possibility that UC-MSCs indirectly regulate CD1c+DCs via PBMCs. Although PBMCs expressed higher level of FLT3L than MSCs, the CD1c+DCs could not be boosted by PBMCs compared with MSCs, suggesting a necessary but not sufficient role of FLT3L in promoting CD1c+DCs. Then in order to detect whether MSCs directly regulated CD1c+DCs, we isolated CD1c+DCs from healthy subjects and showed that MSCs dramatically facilitated the proliferation and inhibited the apoptosis of CD1c+DCs, which was similar to effects of FLT3L to FLT3 binding leading to increased DC cell proliferation and the inhibition of apoptosis. In deed, we not only uncovered that FLT3L was expressed on UC-MSCs, but also showed that FLT3L was expressed on CD1c+DCs. Functionally, UC-MSCs that were pretreated with siRNA against FLT3L have reduced their ability to increase CD1c+DCs. Thus, the data indicated a role of FLT3L in MSCs-mediated upregulation of CD1c+DCs.

We have previously reported that IFN-γ, which was produced predominantly by lupus CD8+ T cells, was a key factor to enhance immune suppressive function of allogeneic MSCs by induction of IDO. We here extended the function of IFN-γ produced by lupus PBMCs or derived from patient serum in regulating MSCs by showing that it increased the expression of FLT3L in MSCs. This was mediated by JAK/STAT signaling pathway.

In addition, we found the UC-MSCs induced CD1c+DCs in the lupus patients exerted tolerogenic properties by decreasing expression of CD80, CD83, CD86 and HLA-DR, decreasing production of TNFα and keeping production of IL-10. These findings suggested the UC-MSCs induced CD1c+DCs could ameliorate immune dysfunction and maintain immune homeostasis, which might be contribute to the benefits of treatment for SLE. Although our findings revealed that after UC-MSCs treatment, not merely the number of CD1c+DCs increased significantly, more than the anti-inflammatory function of these tolerogenic DCs tended to be stronger than before, the connection between the changes of CD1c+DCs and the benefit of treatment in MSC treated patients was still unknown. To answer this question, we further classified the last 10 SLE patients receiving U-MSCT (patient 12–21) into remission group and no remission group. Compared with no remission group, the increases of both frequency and absolute number of CD1c+DCs (post U-MSCT—pre U-MSCST) were significantly higher in remission group (Supplementary Fig. 6). To sum up, we suggested that the increase of CD1c+DCs number induced by MSCs had contribution to the potential benefit of treatment in MSCs treated SLE patients.

It was reported that MSCs employed various mechanisms to regulate immune cells including DCs. For example, HGF and IL-6 have been reported to affect DC maturation and function. We found that in the steady state, MSCs expressed higher levels of IL-6 and HGF compared to FLT3L. Under IFN-γ treatment,
Fig. 4 UC-MSCs up-regulate CD1c+ DCs via FLT3L. a The expression of FLT3L on UC-MSCs was assessed by immunofluorescence staining (Green: FLT3L; Blue: DAPI), white arrows represented FLT3L expression. b The expression of FLT3L on UC-MSCs was assessed by flow cytometry. c CD1c+ DCs are isolated and identified by flow cytometry. Flow cytometry analysis showed the expression of FLT3 on CD1c+ DCs. d The relative expression of FLT3 was compared among isolated CD1c+ DCs (n = 4), CD19+ B cells (n = 4) and CD4+ T cells (n = 3) by real-time PCR. e FLT3L siRNA was used to down-regulate FLT3L expression on UC-MSCs (siFLT3L-MSCs), negative control siRNA treated MSCs (NC-MSCs) were served as controls. The inhibition efficiency of FLT3L siRNA was assessed in UC-MSCs by real-time PCR (n = 3). f FLT3L siRNA was used to down-regulate FLT3L expression on UC-MSCs, then co-cultured with SLE PBMCs, and the frequency of Lin- HLA-DR+ CD1c+ CD1c+ DCs were analyzed (n = 12). g The expression of FLT3L on SLE PBMCs (n = 4) was compared with that on UC-MSCs (n = 3) by real-time PCR. h SLE PBMCs were co-cultured with UC-MSCs (PM group) or autologous PBMCs in which the CD1c+ DCs were deleted (PP group) for 72 h. The frequency of CD1c+ DCs was compared between the two groups. The neutralizing antibody against FLT3L was added to both PM and PP groups, the frequency of CD1c+ DCs was evaluated in each group (n = 9). i The proliferative rate of isolated CD1c+ DCs cultured alone or co-cultured with UC-MSCs for 72 h (n = 5). j The apoptotic rate of isolated CD1c+ DCs cultured alone or co-cultured with UC-MSCs for 24 h (n = 5). k, l FLT3L siRNA was used to down-regulate FLT3L expression on UC-MSCs, NC-MSCs were served as controls, then co-cultured with isolated CD1c+ DCs, the proliferation (k) and apoptosis (l) of isolated CD1c+ DCs were evaluated (n = 3). The experiments were repeated ≥3 times (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by t-test or one-way ANOVA), SEM. Source data were provided as a Source Data file.
MSCs expressed higher levels of IL-6 compared to FLT3L (Supplementary Fig. 17). Blocking either IL-6 (Supplementary Fig. 18) or HGF (Supplementary Fig. 19) had no effect on the progress that MSCs significantly up-regulated the number of CD1c+DCs in vitro (Supplementary Fig. 20). Therefore, we might basically rule out the contribution of IL-6 and HGF on MSCs to promote the up-regulation of CD1c+DCs.

Dendritic cells can be divided into pDCs, CD141+DCs and CD1c+DCs, all with different functions. Therefore, we further investigated the changes of pDCs and CD141+DCs after MSCs treatment. No significant changes of absolute numbers and percentages of pDCs (Supplementary Fig. 7, 12) or CD141+DCs (Supplementary Fig. 8, 13) were observed after MSCs treatment both in vivo and in vitro. These results might further indicate that, rather than other DC subsets, the function of MSCs treatment on the alteration of DCS in lupus patients mainly focused on CD1c+DC subtype; therefore, combining the previous results shown in the manuscript, there seemed to be more evidence to prove the causative connection between MSCs treatment and the improvement of CD1c+DCs.

For the 145 SLE patients included in this study who donated blood for the cell culture and flow cytometry experiments, one patient was newly onset SLE without any medication, the other 144 patients underwent steroid therapy, and 96 underwent immunosuppressant therapy including cyclophosphamide, mycophenolate mofetil, cyclosporine, azathioprine, leflunomide,
tolerogenic circuit. Although the medications taken by patients were observed to be lower than that of controls in this study, which further confirmed that the level of CD1c+DCs were significantly decreased in SLE. Second, the contribution of MSCs to the increase of CD1c+DCs should be compared with that of medications. As CD1c+DCs significantly increased 24 h after U-MSCT, and the medication kept the same during this period, we could basically rule out the contribution of the medication to the increase of CD1c+DCs. Furthermore, 10 SLE patients with lupus nephritis were included, who achieved partial remission after immunosuppressive medications treatment for 1 month. No significant changes of absolute numbers and percentages of CD1c+DCs were observed after the treatment (Supplementary Fig. 9), indicating that the mechanism of traditional immunosuppressive drugs in successfully treating lupus nephritis might not be associated with the number change of CD1c+DCs. This finding was slightly different from previous literature reporting that the immunosuppressive drugs could increase tolerogenic DCs43–47. The contradictory results may be due to several factors including: (1) Most previous studies were in vitro experiment; (2) No previous studies have focused on the changes of CD1c+ DCs.

In summary, we uncovered that CD1c+DCs as critical orchestrators of an immunoregulatory cell network in patients with SLE. We have revealed a previously unrecognized IFNy, FLT3L, FLT3 in allogeneic UC-MSCs-mediated increase in CD1c+DCs in lupus patients. The findings should have implications for MSC therapeutic applications in SLE.

Methods

Subjects

Totally, 166 SLE patients and 78 healthy subjects were included in this study. The average age of the SLE patients and healthy controls were 35.42 ± 12.19 and 34.01 ± 15.18, respectively, and the gender ratio (female/male) of the SLE patients and healthy controls at the same time point by density gradient centrifugation on New York Heart Association functional classification III or IV, hepatic failure, renal failure, or respiratory failure; (3) woman who was pregnant or lactating, or a woman who intended to become pregnant for the next 3 months.

Clinical study of UC-MSCs transplantation for lupus patients was registered in ClinicalTrial.gov (identifier: NCT01741857). This study was approved by the Ethics Committee at the Drum Tower Hospital of Nanjing University Medical School and was conducted in accordance with the principles set forth under the 1989 Declaration of Helsinki.

Isolation, culture and infusion of UC-MSCs

Fresh umbilical cords were obtained with informed consents from healthy mothers in local maternity hospitals after normal deliveries. UC-MSCs for each recipient were from one donor. However, since the clinical effect is clear and consistent, we did not specifically state MSCs heterogeneity in this paper. UC-MSCs were prepared by the Stem Cell Center of Jiangsu Province (Beike Bio-Technology), the umbilical cords, without added penicillin and streptomycin, the cord blood being removed during this process. The washed cords were cut into 1-mm3-sized pieces and floated in DMEM-LG containing 10% FBS. The pieces of cord were subsequently incubated at 37 °C in humid air with 5% CO2. Nonadherent cells were removed by washing. The medium was replaced every 3 days after the initial plating. When well-developed colonies of fibroblast-like cells appeared after 10 days, the cultures were trypsinized and passed into a new flask for further expansion. At 80–85% confluence, the adherent cells were detached by treatment with 0.125% trypsin and 0.1% EDTA.

For preservation, UC-MSCs were resuspended in a cryoprotectant solution composed of 90% FBS and 10% dimethyl sulfoxide (DMSO) (Edwards Lifesciences) and stored at −80 °C overnight, then transferred to the vapor phase of a liquid nitrogen tank. Frozen cells were thawed for clinical-scale expansion using the same protocol as described for primary expansion. Cells from passage 2 to 5 were harvested during the second expansion period. After rinsing twice with PlasmaLyte-A (Baxter), penicillin and streptomycin, the umbilical cord was minced, and was suspended in a serum albumin (Hualan Biological Engineering Inc.). The majority of remaining cells were packaged in 25 ml disposable plastic blood bags (10 million cells in 10 ml volume) (Shandong Weigao Group Medical Polymer Company Limited).

Criteria for release of UC-MSCs for clinical use included spindle-shaped morphology, absence of visible clumps and absence of cell supernatant contamination by pathogens, as well as by virus for hepatitis B surface antigen, hepatitis B core antibody, hepatitis C virus antibody, human immunodeficiency virus antibodies I and II, cytomegalovirus IgM, and syphilis antibody, and cell viability greater than 92%. Immunophenotype analysis indicated that the cultured UC-MSCs were positive expression of CD45, CD14, CD105, CD73, CD90, CD 135 (>90%) and negative expression of CD45, CD34, CD14, CD79a, and HLA-DR (<2%).

Two-weekly patients underwent UC-MSCs transplantation. All patients underwent U-MSCT and one million cells per kilogram of body weight were administrated by intravenous infusion, without adding steroid or other immunosuppressive drugs. After successful expansion in vitro, the doses of immunosuppressive drugs were tapered according to the amelioration of disease conditions. If the clinical index was not improved or if disease activity had not declined, the drug dose was not tapered or new drugs might be chosen. When relapse occurred, the dose of prednisone could be added or new drugs would be given.

Isolation and culture of PBMCs

PBMCs were isolated from active lupus patients and healthy controls at the same time point by density gradient centrifugation from Ficoll, and PBMCs were resuspended in PBS containing 1% bovine serum albumin and 0.1% sodium azide. In vitro experiments, recombinant human FLT3L was added to PBMCs. After 72 h culture, cells were harvested for examining by flow cytometry. Also, PBMCs were co-cultured with UC-MSCs for 72 h at a ratio of 10:1, and supernatants were collected after centrifugation.

Antibodies and reagents

The following antibodies (to humans) were used in this study: fluorescein isothiocyanate (FITC)-conjugated anti-human hematopoietic lineage cocktail (eBioscience), phycoerythrin (PE)-conjugated anti-human CD1c (eBioscience), anti-human CD133 (FLT3) (eBioscience), anti-human CD123 (eBioscience), anti-human CD141 (BD Biosciences), allophycocyanin (APC)-conjugated anti-human CD11c (eBioscience), PE-Cy7-conjugated anti-human HLA-DR (eBioscience), BV711-conjugated anti-human CD40 (BioLegend), PE-Dazzle594-conjugated anti-human CD90 (BioLegend), anti-human TNFα (BioLegend), APC-Cy7-conjugated anti-human CD83 (BioLegend), anti-human CD1c (BioLegend), BV605-conjugated anti-human CD86 (BioLegend), BV421-conjugated anti-human IL-10 (BioLegend), PerCP-Cy5.5-conjugated anti-human CD11c (BioLegend) and their respective isotype-matched control antibodies (mouse IgG1, mouse IgG2a, mouse IgG2b, rat IgG1x) were from eBioscience. Cell Proliferation Dye eFluor® 670 was from eBioscience. Annexin V/7AAD apoptosis detection kit Annexin V was from BD Biosciences. Anti-FLT3 ligand antibody (ab52648) and its isotype-control Rabbit IgG, monoclonal were both from Abcam. Anti-Fli3 ligand monoclonal antibody (ab96882) was from Abcam, anti-human TNFα neutralizing antibody were from R&D Systems. Human FLT3L was from PeproTech. Human FLT3L, Quantikine ELISA Kit was from R&D Systems. Human CD1c (BDA-1)® DC Isolation Kit was from Miltenyi Biotec.

Isolation and culture of PBMCs

PBMCs were isolated from active lupus patients and healthy controls at the same time point by density gradient centrifugation from Ficoll, and PBMCs were resuspended in PBS containing 1% bovine serum albumin and 0.1% sodium azide. In vitro experiments, recombinant human FLT3L was added to PBMCs. After 72 h culture, cells were harvested for examining by flow cytometry. Also, PBMCs were co-cultured with UC-MSCs for 72 h at a ratio of 10:1, and supernatants were collected after centrifugation.
Isolation of CD1c+ DCs. CD1c+ DCs were purified with magnetic cell sorting (MACS) using anti-CD1c (BDCA-1) micro beads according to the manufacturer’s instructions. In brief, CD19+ cells were depleted using anti-CD19-coated magnetic beads, and then CD1c+ cells were isolated using biotinylated anti-CD1c and anti-biotin–beads.

Flow cytometry analysis and ELISA. For the detection of intracellular cytokines, the PBMCs were stimulated at 37 °C for 6 h with 1 μg/ml LPS (Sigma) or 4 μg/ml CD40L (Invitrogen), in the presence of 10 μg/ml brefeldin A (Enzo), 20 μg/ml phorbol-12-myristate-13-acetate (Enzo) and 1 μg/ml ionomycin (Enzo) during the last 4 h of stimulation. For the detection of changes in surface antigen expression, the PBMCs were stimulated at 37 °C for 6 h with 1 μg/ml LPS (Sigma). In brief, CD19+ cells were depleted with magnetic cell sorting (MACS) using anti-CD1c (BDCA-1) micro beads, and then CD1c+ beads were exposed to goat anti-rabbit immunoglobulin G conjugated to fluorescein isothiocyanate, Alexa-488 (dilution 1:1000) (MultiSciences) for 1 h at room temperature, followed by nuclear staining with DAPI for 5 min. After three rinses in PBS, coverslips were mounted on slides. The cells on coverslips were examined using a biological imaging (FSX100, Olympus).

Statistical analysis. We used the t-test or chi-square test for statistical analysis for parametric data and the Mann–Whitney U-test for non-parametric data. One-way analysis of variance was used when there were more than two groups, and then followed by Least-Significant Difference (LSD) test among different groups. We performed statistical analyses with SPSS16.0 software and GraphPad Prism 4.3 and considered a P value <0.05 as significant difference. Data are shown as means ± standard error of mean (SEM).

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability. The data that support the findings of this study are available on request from the corresponding author. The source data underlying Figs. 1c–i, 2a–b, 3b–d, 3f–l, 4d–l, 5a–e, 5h, and Supplementary Figs. 1–5 and 17–24 are provided as a Source Data file.

Received: 29 August 2018 Accepted: 14 May 2019 Published online: 07 June 2019

Table 3 Primers for real-time polymerase chain reaction

| Gene     | Forward                                      | Reverse                                      |
|----------|----------------------------------------------|----------------------------------------------|
| FLT3L    | 5′-TCCTTCGCTCCAGACCA-3′                       | 5′-CCAGTCTAGCTCCACAAAG-3′                    |
| FLT3     | 5′-AGGAGCTTAGTAGGAGCGTG-3′                   | 5′-GCTGCTGATCTACAGACAGGAG-3′                 |
| IL-6     | 5′-ACTCAACCTTCAAGAGAGTCTG-3′                 | 5′-CATTCTTGGAGGTCTACAGTG-3′                  |
| HGF      | 5′-GCTACGCGGTTAAAGACCTCA-3′                  | 5′-CATAGCGTACCTGAGTGGC-3′                    |
| GAPDH    | 5′-ATGGGAAGGTTGAAGGTCG-3′                    | 5′-GGGCGTATTAGGGCACAATA-3′                   |

Non-specific binding sites were blocked with 10% goat serum for 30 min at room temperature. Cells were then incubated overnight at 4 °C or 1 h at room temperature with primary antibody (Anti-FLT3 ligand antibody). After three rinses in PBS, cells were exposed to goat anti-rabbit immunoglobulin G conjugated to fluorescein isothiocyanate, Alexa-488 (dilution 1:1000) (MultiSciences) for 1 h at room temperature, followed by nuclear staining with DAPI for 5 min. After three rinses in PBS, coverslips were mounted on slides. The cells on coverslips were examined using a biological imaging (FSX100, Olympus).

References

1. Lipsky, P. E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. 2, 764–766 (2001).
2. Carroll, M. C. A protective role for innate immunity in systemic lupus erythematosus. Nat. Rev. Immunol. 4, 825–831 (2004).
3. Vega-Ramos, J., Roquilly, A., Asehnoune, K. & Villadangos, J. A. Modulation of dendritic cell antigen presentation by pathogens, tissue damage and secondary inflammatory signals. Curr. Opin. Pharmacol. 17, 64–70 (2014).
4. Chan, V. S. et al. Distinct roles of myeloid and plasmacytoid dendritic cells in systemic lupus erythematosus. Autoimmun. Rev. 11, 890–897 (2012).
5. Mok, M. Y. Tolerogenic dendritic cells: role and therapeutic implications in systemic lupus erythematosus. Int. J. Rheum. Dis. 18, 250–259 (2015).
6. Liu, J. & Cao, X. Regulatory dendritic cells in autoimmunity: a comprehensive review. J. Autoimmun. 63, 1–12 (2015).
7. Jongbloed, S. L. et al. Human CD141+ (BDCA-3)-+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J. Exp. Med. 207, 1247–1260 (2010).
8. Kassianos, A. J. et al. Human CD1c (BDCA-1)+ myeloid dendritic cells secrete IL-10 and display an immune-regulatory phenotype and function in response to Escherichia coli. Eur. J. Immunol. 42, 1512–1522 (2012).
9. Qian, C. & Cao, X. Naturally occurring CD1c-+ human regulatory dendritic cells: immunoregulators that are expanded in response to E. coli infection. Eur. J. Immunol. 42, 1388–1392 (2012).
10. Bamboat, Z. M. et al. Human liver dendritic cells promote T cell hyporesponsiveness. J. Immunol. 182, 1901–1911 (2009).
11. Tsoukamidou, M. et al. Tolerogenic signaling by pulmonary CD1c+ dendritic cells induces regulatory T cells in patients with chronic obstructive pulmonary disease by IL-27/IL-10-inducible costimulator ligand. J. Allergy Clin. Immunol. 134, 944–954 (2014).
12. Waskow, C. et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat. Immunol. 9, 676–683 (2008).
13. Merad, M. & Manz, M. G. Dendritic cell homeostasis. Blood 113, 3418–3427 (2009).

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10491-8
ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10491-8
14. Stirewalt, D. L. & Radich, J. P. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer 3, 650–665 (2003).

15. Breton, G. et al. Circulating precursors of human CD1c+ and CD14+ dendritic cells. J. Exp. Med. 212, 401–413 (2015).

16. Ding, Y. et al. FLT3-ligand treatment of humanized mice results in the generation of large numbers of CD141+ and CD1c+ dendritic cells in vivo. J. Immunol. 192, 1982–1989 (2014).

17. Lozinski, M. et al. Human mesenchymal stem cells inhibit the differentiation of antigen-presenting dendritic cells. Cell. Stem. Cell. 10, 709–716 (2012).

18. Wang, Y. et al. Mesenchymal stem cell-mediated immunosuppression occurs via a glucocorticoid-dependent mechanism. Nat. Med. 15, 1009–1016 (2014).

19. Jiang, X. et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105, 4120–4126 (2005).

20. Ren, G. et al. Mesenchymal stem cell-mediated immunosuppression occurs via a glucocorticoid-dependent mechanism. Stem Cells Transl. Med. 5, 1055–1064 (2016).

21. Ren, G. et al. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 83, 71–76 (2007).

22. Beryt, S. et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105, 2214–2221 (2005).

23. Maccario, R. et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90, 516–525 (2005).

24. Wang, D. et al. CD1+ dendritic cells in bone marrow are derived from a CD1c+ dendritic cell precursor population. J. Exp. Med. 218, 28–35 (2010).

25. Ren, G. et al. Mesenchymal stem cell-mediated immunosuppression occurs via a glucocorticoid-dependent mechanism. J. Immunol. 193, 3036–3044 (2014).

26. Wang, D. et al. Mesenchymal stem cell-mediated immunosuppression occurs via a glucocorticoid-dependent mechanism. J. Immunol. 193, 3036–3044 (2014).

27. Hahn, B. H. et al. The active metabolite of leflunomide is the primary therapeutic target in patients treated with branded and generic leflunomide. Arthritis Res. Ther. 17, R275 (2015).

28. Hahn, B. H. et al. The active metabolite of leflunomide is the primary therapeutic target in patients treated with branded and generic leflunomide. Arthritis Res. Ther. 17, R275 (2015).

29. Hahn, B. H. et al. The active metabolite of leflunomide is the primary therapeutic target in patients treated with branded and generic leflunomide. Arthritis Res. Ther. 17, R275 (2015).